跳至主要内容
临床试验/CTRI/2011/091/000041
CTRI/2011/091/000041已完成4 期

Assessment of Efficacy, Safety and Tolerability of D?acne (Clindamycin Phosphate 1% and zinc acetate) in the treatment of Acne.

Glenmark Pharmaceuticals Ltd0 个研究点目标入组 125 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
125

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • ?Subjects with mild to moderate inflammatory acne with comedones, papules or pustules predominate (Grade 1 and grade 2, IADVL acne grading system) affecting face
  • ?Subjects must be 18-40 years of age
  • ?Subjects must provide written informed consent and comply to the protocol

排除标准

  • ?Subjects not willing to discontinue all topical treatments for Acne for 2 weeks prior to enrollment in study
  • ?Hypersensitivity to any ingredients of D?acne
  • ?Pregnant and lactating women.
  • ?Subjects taking Concomitant therapy that might interfere with the study results in the investigator?s opinion.
  • ?Subjects with dermatological disorder of face that may interfere with study evaluation.

研究者

发起方
Glenmark Pharmaceuticals Ltd

相似试验